Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 13/20 | 1.00 |
| ▸ | PKLR | P30613 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19871300 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL29945828 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL17808925 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL19858525 | 0.88 | PKM (0.77) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL20457189 | 0.86 | PKM (0.75) | PKMPKLRNPC1RAB9A | |
| SCHEMBL31315853 | 0.84 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL1722721 | 0.84 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL23598057 | 0.84 | PKM (0.73) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL20456955 | 0.84 | PKM (0.73) | PKMPKLRHTTALDH1A1 | |
| SCHEMBL19871299 | 0.84 | PKM (0.73) | PKMPKLRHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465780-B2 | Adjusting tumor treating fields simulation and treatment using molecular imaging | NOVOCURE GMBH (CH) | 2025-11-11 | — | — | US | claimed |
| EP-4387710-A1 | ADJUSTING TUMOR TREATING FIELDS SIMULATION AND TREATMENT USING MOLECULAR IMAGING | Novocure GmbH (CH) | 2024-06-26 | — | — | EP | claimed |
| CN-118251256-A | Modeling and treatment for modulating tumor electric field therapy using molecular imaging | 诺沃库勒有限责任公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2023084340-A1 | ADJUSTING TUMOR TREATING FIELDS SIMULATION AND TREATMENT USING MOLECULAR IMAGING | NOVOCURE GMBH (CH) | 2023-05-19 | — | — | WO | claimed |
| US-20230149728-A1 | ADJUSTING TUMOR TREATING FIELDS SIMULATION AND TREATMENT USING MOLECULAR IMAGING | NOVOCURE GMBH (CH) | 2023-05-18 | — | — | US | claimed |
| CN-115243720-A | Method for normalizing abnormal glycolytic metabolism in cancer cells | 利兰·斯坦福青年大学托管委员会 | 2022-10-25 | — | — | CN | claimed |
| US-12465780-B2 | Adjusting tumor treating fields simulation and treatment using molecular imaging | NOVOCURE GMBH (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4387710-A1 | ADJUSTING TUMOR TREATING FIELDS SIMULATION AND TREATMENT USING MOLECULAR IMAGING | Novocure GmbH (CH) | 2024-06-26 | — | — | EP | disclosed |
| CN-118251256-A | Modeling and treatment for modulating tumor electric field therapy using molecular imaging | 诺沃库勒有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023084340-A1 | ADJUSTING TUMOR TREATING FIELDS SIMULATION AND TREATMENT USING MOLECULAR IMAGING | NOVOCURE GMBH (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230149728-A1 | ADJUSTING TUMOR TREATING FIELDS SIMULATION AND TREATMENT USING MOLECULAR IMAGING | NOVOCURE GMBH (CH) | 2023-05-18 | — | — | US | disclosed |
| EP-4081257-A1 | METHODS OF NORMALIZING ABERRANT GLYCOLYTIC METABOLISM IN CANCER CELLS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115243720-A | Method for normalizing abnormal glycolytic metabolism in cancer cells | 利兰·斯坦福青年大学托管委员会 | 2022-10-25 | — | — | CN | disclosed |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-29 | — | — | US | disclosed |
| EP-2704719-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | Agios Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151450-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
| EP-2344453-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042867-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK2, PCK2 | PKM 14/4885PKLR 26/4885NPC1 3312/4885 |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 5/4885PKLR 7/4885NPC1 4729/4885 |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 7/4885NPC1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.